Perspective Therapeutics, Inc.
As of Oct 22, 2026, Perspective Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $2.26, 60.0% below its 52-week high and below its 200-day average, which is falling.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CATX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CATX among Medical Devices67th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …67 | CATX | Stage 4 · wk 6 | 35 | −13.7% |
Perspective Therapeutics: quick answers
What stage is Perspective Therapeutics in?
As of Oct 22, 2026, Perspective Therapeutics (CATX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Perspective Therapeutics in an uptrend?
No. Perspective Therapeutics is in a Stage 4 downtrend. It trades 36.9% below its 200-day average, which is falling.
How far is Perspective Therapeutics from its 52-week high?
Perspective Therapeutics closed at $2.26 on Oct 22, 2026, 60.0% below its 52-week high of $5.65. Its 52-week low is $2.05.
How has Perspective Therapeutics performed over the past year?
As of Oct 22, 2026, Perspective Therapeutics is down 27.3% over the past year and down 19.0% so far in 2026.
Which sector and industry is Perspective Therapeutics in?
Perspective Therapeutics is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.